Department of Biomedical Sciences
United States of America
Dr.James Denvir in this research is as a biostatistician and bioinformaticist. As a collaborative researcher,he aim to maintain a full understanding of current statistical techniques, to determine which of those techniques are best applied to problems presented by the generation of data from biomedical research, to maintain the technical skills to perform those analyses, and to present and communicate the results to the research community at large. A key aspect to this collabortive research, is the ability to communicate with researchers outside one’s own field; both in terms of understanding the research being performed in the lab, and in terms of being able to explain the choices behind the analyses being used and their results. On occasion, it may be necessary to develop novel statistical techniques in order to perform the analyses required for a particular project. He is specifically interested in research in complex disease, including cancer and cardiovascular disease.His interest stems both from an “applied” perspective (these are diseases in which our understanding and consequently our abilities to provide treatment have the greatest potential for further progress), and from a “theoretical” perspective (the mathematical relationships between the various causes of the disease and its manifestation are intellectually appealing to him). His particular expertise is in the application of multiple hypothesis testing procedures to high-throughput genomic data. I am interested in the future to combine different sources of genomic data (such as sequence data, gene expression data, microRNA expression data, methylation data, and proteomic data) to achieve a more global understanding of the molecular mechanisms of disease. At the clinical level, this translates to pursuing a unified understanding of the interaction of “traditional” genomics with the molecular effects of environment and its effect on disease.
cancer and cardiovascular disease
A novel network model identified a 13-gene lung cancer prognostic signature. Guo NL, Wan YW, Bose S, Denvir J, Kashon ML, Andrew ME. Int J Comput Biol Drug Des. 2011;4(1):19-39. doi: 10.1504/IJCBDD.2011.038655. Epub 2011 Feb 17.
Bone marrow osteoblast damage by chemotherapeutic agents. Rellick SL, O’Leary H, Piktel D, Walton C, Fortney JE, Akers SM, Martin KH, Denvir J, Boskovic G, Primerano DA, Vos J, Bailey N, Gencheva M, Gibson LF. PLoS One. 2012;7(2):e30758. Epub 2012 Feb 17.
Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cieply B, Riley P 4th, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, Denvir J, Frisch SM. Cancer Res. 2012 May 1;72(9):2440-53. Epub 2012 Feb 29.